# A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration

> **NCT06660667** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sanofi** · enrollment: 66 (estimated)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **BIOLOGICAL:** SAR402663
- **DRUG:** Diluent

## Key facts

- **NCT ID:** NCT06660667
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-21
- **Primary completion:** 2027-05-18
- **Final completion:** 2031-06-30
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06660667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06660667, "A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06660667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*